# US 2023/0047753 A1 · Viral vectors for enhanced ultrasound-mediated delivery to the brain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0047753 A1
- Document ID: US20230047753A1
- Status: Published application
- Kind: A1
- Application number: 17/814,384
- Filed: 2022-07-22
- Published: 2023-02-16
- Earliest claimed: 2021-07-23
- Applicants: California Institute of Technology
- Inventors: Jerzy O. Szablowski; Hongyi Li; John E. Heath; Mikhail G. Shapiro
- Web page: https://patentgrep.com/patent/US20230047753A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C12N 15/8616: {Special methods for targeting systems}
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein include adeno-associated virus (AAV) acoustic targeting peptides. An AAV comprising the AAV acoustic targeting peptide can exhibit increased transduction at site(s) of focused ultrasound blood-brain barrier opening (FUS-BBBO), increased neuronal tropism, and diminished transduction of peripheral organs. Disclosed herein include recombinant adeno-associated virus (rAAV) comprising an AAV acoustic targeting peptide disclosed herein. Also provided herein include methods of delivering an agent to one or more target brain region(s) of a subject.

## Claims

### Claim 1

An adeno-associated virus (AAV) acoustic targeting peptide comprising an amino acid sequence that comprises at least 4 contiguous amino acids from a sequence selected from the group consisting of AGNTSDR (SEQ ID NO: 1), ATDAYNK (SEQ ID NO: 2), WSEGGQP (SEQ ID NO: 3), SVGSADP (SEQ ID NO: 4), and VRMEGEV (SEQ ID NO: 5).

### Claim 2 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide comprises AGNTSDR (SEQ ID NO: 1).

### Claim 3 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide comprises ATDAYNK (SEQ ID NO: 2).

### Claim 4 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide comprises WSEGGQP (SEQ ID NO: 3).

### Claim 5 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide comprises SVGSADP (SEQ ID NO: 4).

### Claim 6 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide comprises VRMEGEV (SEQ ID NO: 5).

### Claim 7 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide is part of a capsid protein of an AAV.

### Claim 8 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide is conjugated to a nanoparticle, a second molecule, a viral capsid protein, or a combination thereof.

### Claim 9 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein the AAV acoustic targeting peptide is configured enhance the focused ultrasound (FUS)-target specificity of FUS blood-brain-barrier opening (FUS-BBBO)-mediated transduction.

### Claim 10 (depends on 1)

The AAV acoustic targeting peptide of claim 1, wherein an AAV comprising the AAV acoustic targeting peptide demonstrates
an at least about 1.1-fold increase in transduction at site(s) of FUS-BBBO;
an at least about 1.1-fold increase in neuronal tropism; and/or
an at least about 1.1-fold decrease in transduction in peripheral organs
as compared to the corresponding parental AAV that does not comprise the acoustic targeting peptide.

### Claim 11 (depends on 1)

An adeno-associated virus (AAV) capsid protein comprising the AAV acoustic targeting peptide of claim 1.

### Claim 12 (depends on 11)

The AAV capsid protein of claim 11, wherein the AAV capsid is derived from AAV9, or a variant thereof.

### Claim 13 (depends on 1)

A nucleic acid, comprising a sequence encoding the AAV acoustic targeting peptide of claim 1.

### Claim 14 (depends on 1)

A recombinant adeno-associated virus (rAAV), comprising the AAV acoustic targeting peptide of claim 1.

### Claim 15 (depends on 1)

A recombinant adeno-associated virus (rAAV), comprising an AAV capsid protein which comprises the AAV acoustic targeting peptide of claim 1, wherein the amino acid sequence is inserted between two adjacent amino acids in AA586-592, or functional equivalents thereof, of the AAV capsid protein.

### Claim 16 (depends on 15)

The rAAV of claim 15, wherein the AAV capsid protein comprises, or consists thereof, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and/or SEQ ID NO: 10.

### Claim 17 (depends on 1)

A composition for use in the delivery of an agent to a target environment of a subject, comprising an AAV comprising (1) an AAV capsid protein comprising an AAV acoustic targeting peptide of claim 1 and (2) an agent to be delivered to the target environment of the subject, wherein the target environment comprises one or more target brain region(s), and wherein the agent to be delivered comprises a nucleic acid, a peptide, a small molecule, an aptamer, or a combination thereof.

### Claim 18

A method of delivering an agent to one or more target brain region(s) of a subject, the method comprising:
providing an AAV vector comprising an AAV capsid protein comprising an AAV acoustic targeting peptide, wherein the AAV acoustic targeting peptide comprises an amino acid sequence that comprises at least 4 contiguous amino acids from a sequence selected from the group consisting of AGNTSDR (SEQ ID NO: 1), ATDAYNK (SEQ ID NO: 2), WSEGGQP (SEQ ID NO: 3), SVGSADP (SEQ ID NO: 4), and VRMEGEV (SEQ ID NO: 5), and wherein the AAV vector further comprises an agent to be delivered to the one or more target brain region(s); and
administering the AAV vector to the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the method further comprises:
administering to the subject an effective amount of a microbubble contrast agent; and
applying focused ultrasound (FUS) to the one or more target brain region(s) of the subject.

### Claim 20

A method of treating or preventing a disease or disorder in a subject in need thereof, comprising:
administering to the subject an effective amount of an AAV vector comprising an AAV capsid protein comprising an AAV acoustic targeting peptide, wherein the AAV acoustic targeting peptide comprises an amino acid sequence that comprises at least 4 contiguous amino acids from a sequence selected from the group consisting of AGNTSDR (SEQ ID NO: 1), ATDAYNK (SEQ ID NO: 2), WSEGGQP (SEQ ID NO: 3), SVGSADP (SEQ ID NO: 4), and VRMEGEV (SEQ ID NO: 5), and wherein the AAV vector further comprises an agent to be delivered to the one or more target brain region(s);
administering to the subject an effective amount of a microbubble contrast agent; and
applying focused ultrasound (FUS) to one or more target brain region(s) of the subject,
thereby treating or preventing the disease or disorder in the subject.
